Glenmark Pharmaceuticals Ltd. is a research-driven, global, fully integrated pharmaceutical company headquartered at Mumbai, India. It employs over 4100 people across its global operations and its shares are listed on India’s two large stock exchanges, the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
The Company is a leader in India in the discovery of new molecules (both NCES and Biologics) and is focused in the areas of inflammation [Asthma/COPD, etc] and metabolic disorders [Diabetes, Obesity, etc]. Glenmark has built a visible and growing branded generic formulation presence across all its markets in Latin America, Europe, Asia, Africa and CIS countries. A number of its products have emerged as brand leaders in India and some of these markets. Glenmark has made acquisitions in Brazil, South Africa and Czech Republic and is currently looking to acquire companies in Europe.
Research lies at the heart of Glenmark’s business as affirmed in its vision. Glenmark is among the few Indian pharmaceutical players targeting new drug discovery research. Today, Glenmark has a pipeline of 13 molecules; six of which are in clinical development and the other seven are at various stages of preclinical development and discovery. The Company has been able to build an admirable pipeline of molecules within a short span in the targeted areas of inflammation and metabolic disorders. The Company’s new drug discovery research is carried out at its state-of-the-art research centre at Mahape, in Navi Mumbai. Glenmark’s biopharmaceutical research is carried out in its research centre in Switzerland. This facility was established with an aim to diversify into research activities to cover biologics and now has a team of more than 50 scientists with Biologics Research experience, from Switzerland and Europe.
in the Czech Republic & Slovak Republic
Glenmark is continuously advancing the number of countries where it sells, as well as produces, its medicinal products. It has recently expanded also to the Czech & Slovak Republic. In 2007, the company Glenmark Pharmaceuticals bought over ninety percent of the shares in the pharmaceutical company Medicamenta which subsequently changed its business name to Glenmark Pharmaceuticals.
Pharmaceutical production has a long history with Medicamenta. It started sometimes in the fifties. At the present, Medicamenta is a modern and flexible pharmacetical company with business offices in Prague and Bratislava and production plant at Vysoké Mýto. Medicamenta is certified by the Czech regulatory authority SÚKL (State Institute for Drug Control). Medicamenta also holds the authorisation for imports from 3rd countries.
Glenmark is moving a considerable amount of its production to the Vysoké Mýto, as well as the final packaging of the medicinal products for the whole central and eastern part of the European Union.